Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pressure Mounts On Zydus Cadila In Q3 As Vaccine Launch Looms

Indian Firm May See Fortunes Change As ZyCov-D And Biosimilars Reach Market

Executive Summary

Zydus Cadila found itself under pressure during Q3 following a lack of demand for COVID-19 therapeutics in India and reduced mesalamine sales in the US – but, heading into H2, exports of its novel COVID-19 vaccine ZyCov-D, as well as a number of biosimilar launches, could see its luck begin to turn.

You may also be interested in...

Shilpa Eyes History At It Nudges Closer To Aflibercept Opportunity In India

Amid growing moves in India for local manufacturers to make and supply biosimilars, Shilpa’s biologics division has moved a step closer to becoming the first Indian company to initiate clinical trials for a biosimilar to Regeneron’s Eylea treatment for ophthalmic diseases.

Zydus Mounts Challenge To Novartis With Generic Nelarabine Injection

Zydus Cadila’s single-dose nelarabine injection (250mg/50ml) will enjoy 180 days of competitive generic therapy market exclusivity following approval from the US FDA, as the first approved rival to Novartis’ Arranon brand.

Mifepristone Access Swings In The Balance In Post-Roe World

The US Supreme Court has overturned Roe v. Wade, but numerous avenues could help to preserve access to abortion drug mifepristone – if legislators and lawmakers are willing to walk down them.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts